Endoscopic screening for gastrointestinal cancers

Precise estimates of the magnitude of benefits and harms of endoscopic screening for cancer are a prerequisite for informed decision making for or against participation in screening for individuals in the target population.

Photo: Colourbox

In the paper Do’s and don’ts in evaluation of endoscopic screening for gastrointestinal cancers published online first in the journal Endoscopy on Sept 21st, Michael Bretthauer and co-workers from the Clinical Effectiveness Research group outline the most common pitfalls in the evaluation of screening and offer recommendations for future studies.

Latest publications

Eilertsen et al. 2020. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. 469: 246-255 Araghi et al. 2020. Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut [Online ahead of print] Lopes et al. 2020. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer [Online ahead of print] Bruun et al. 2020. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin. Cancer Res. [Online ahead of print] Brunsell et al. 2020. High concordance and negative prognostic impact of RAS/BRAF/PIK3CA mutations in multiple resected colorectal liver metastases. Clin. Colorectal Cancer [Online ahead of print] All publications